International Journal of Medical Science and Pharmaceutical Research

ISSN(e): 3050-5720
ISSN(p): 3050-5712

Vol. 3 (4): 160-163, April 2026

Home Page: https://ijmspr.org/

Hyperhomocysteinemia Beyond Supplementation: A Practical Clinical Approach to Resistant Cases

Jozelio F Carvalho
Institute for Health Sciences, Federal University of Bahia

KEYWORDS:
Hyperhomocysteinemia, Homocysteine metabolism, Methylation imbalance, Transsulfuration pathway, Refractory hyperhomocysteinemia, Functional metabolic blockade

Corresponding Author:
Jozelio F Carvalho

DOI: 10.55677/IJMSPR/2026-3050-I410

Published: April 23, 2026

ABSTRACT

Hyperhomocysteinemia is a well-established and modifiable risk factor associated with cardiovascular disease, stroke, cognitive decline, and systemic inflammation. Conventional therapeutic approaches based on folate, vitamin B12, and vitamin B6 supplementation are widely implemented and frequently effective. However, a subset of patients presents persistent elevations in homocysteine levels despite adequate or supraphysiological concentrations of these cofactors. This paradox highlights the complexity of homocysteine metabolism and suggests the presence of functional metabolic dysregulation rather than simple nutrient deficiency. This narrative review provides a comprehensive and clinically oriented framework integrating biochemical pathways, conventional therapies, and advanced metabolic reasoning in cases of treatment resistance. Particular emphasis is placed on methylation imbalance, impaired transsulfuration, and the concept of functional metabolic blockade. A practical, physiology-based approach is proposed to guide clinicians in the management of refractory hyperhomocysteinemia.

Cite the Article: *Carvalho, J.F. (2026). Hyperhomocysteinemia Beyond Supplementation: A Practical Clinical Approach to Resistant Cases. International Journal of Medical Science and Pharmaceutical Research, 3(4), 160-163. https://doi.org/10.55677/IJMSPR/2026-3050-I410*

1. INTRODUCTION

Hyperhomocysteinemia has been consistently associated with increased risk of cardiovascular and cerebrovascular disease, as well as neurodegenerative conditions and overall mortality. Elevated plasma homocysteine levels contribute to endothelial dysfunction, oxidative stress, vascular inflammation, and thrombogenesis, representing a relevant and modifiable risk factor in clinical practice [1–3]. Despite its apparent biochemical simplicity, homocysteine metabolism involves a complex network of enzymatic pathways and regulatory mechanisms that extend beyond the classical paradigm of vitamin deficiency.

Traditional therapeutic strategies focus on supplementation with folic acid, vitamin B12, and vitamin B6, aiming to restore remethylation and transsulfuration pathways. While this approach is effective in many patients, clinical experience reveals that a subset remains with persistently elevated homocysteine levels despite adequate or even excessive supplementation. This observation challenges the reductionist model of deficiency correction and suggests the presence of functional disturbances in metabolic flux, enzymatic activity, or pathway integration.

This review aims to provide a clinically applicable framework for understanding and managing resistant hyperhomocysteinemia, emphasizing the transition from a deficiency-based model to a systems-oriented metabolic approach.

2. BIOCHEMISTRY OF HOMOCYSTEINE METABOLISM

Homocysteine is an intermediary sulfur-containing amino acid derived from methionine metabolism and occupies a central position in cellular methylation and redox balance. It is metabolized through two main pathways: remethylation and transsulfuration (see Figure 1).

The remethylation pathway regenerates methionine from homocysteine through methionine synthase, a reaction dependent on vitamin B12 and 5-methyltetrahydrofolate. This process is crucial for maintaining adequate levels of S-adenosylmethionine (SAMe), the universal methyl donor involved in DNA methylation, neurotransmitter synthesis, and phospholipid metabolism [4]. An alternative remethylation pathway occurs in the liver via betaine-homocysteine methyltransferase (BHMT), utilizing trimethylglycine (betaine) as a methyl donor.

In contrast, the transsulfuration pathway irreversibly converts homocysteine into cystathionine and subsequently cysteine through the action of cystathionine beta-synthase (CBS) and cystathionine gamma-lyase, both of which require vitamin B6 as a cofactor. This pathway is essential for glutathione synthesis, redox homeostasis, and detoxification processes [5].

The balance between these pathways determines plasma homocysteine levels and reflects the integration between methylation demand and antioxidant capacity.

3. CLINICAL IMPLICATIONS OF HYPERHOMOCYSTEINEMIA

Elevated homocysteine levels have been associated with multiple pathological processes. Mechanistically, homocysteine induces endothelial dysfunction by reducing nitric oxide bioavailability, increasing oxidative stress, and promoting inflammatory responses within the vascular wall [2,6]. These effects contribute to atherogenesis and increase the risk of cardiovascular events.

Epidemiological studies have demonstrated a consistent association between hyperhomocysteinemia and coronary artery disease, stroke, and peripheral vascular disease [1,7]. In addition, elevated homocysteine has been linked to cognitive decline, dementia, and neurodegenerative disorders, possibly through mechanisms involving excitotoxicity, oxidative stress, and impaired methylation [8].

Despite strong associations, interventional trials using vitamin supplementation have yielded mixed results in reducing clinical outcomes, suggesting that homocysteine may function not only as a causal factor but also as a marker of broader metabolic dysregulation [9].

4. CONVENTIONAL THERAPEUTIC STRATEGIES

The conventional treatment of hyperhomocysteinemia is based on supplementation with folic acid, vitamin B12, and vitamin B6, aiming to enhance remethylation and transsulfuration pathways. Folic acid has been shown to effectively reduce homocysteine levels, particularly in populations with low baseline folate intake [10]. Vitamin B12 supplementation is essential in cases of deficiency and enhances methionine synthase activity, while vitamin B6 supports the transsulfuration pathway.

Riboflavin has also emerged as a relevant cofactor, particularly in individuals with MTHFR polymorphisms, where it may improve enzyme efficiency and reduce homocysteine levels [11]. Betaine (trimethylglycine) provides an alternative methyl donor through the BHMT pathway and has been used as an adjunct in selected cases.

Although these strategies are generally effective, they assume that hyperhomocysteinemia results primarily from insufficient cofactor availability, an assumption that does not hold true in all clinical scenarios.

5. THE PARADOX OF PERSISTENT HYPERHOMOCYSTEINEMIA

In clinical practice, some patients exhibit persistent elevations in homocysteine levels despite normalization or elevation of serum folate, vitamin B12, and vitamin B6. This paradox suggests that homocysteine metabolism may be impaired at a functional or regulatory level rather than due to substrate deficiency.

This condition highlights the importance of considering metabolic flux, intracellular utilization of cofactors, and the dynamic balance between methylation and transsulfuration pathways. In such cases, further supplementation may not only be ineffective but may also exacerbate metabolic imbalance.

6. MECHANISMS OF TREATMENT RESISTANCE

One potential mechanism underlying treatment resistance is excessive methylation drive. High doses of methyl donors such as SAMe, methylcobalamin, methylfolate, and betaine may lead to an imbalance in the SAM/SAH ratio, resulting in feedback inhibition of methylation-dependent enzymes and impaired metabolic flux [12]. This state, sometimes referred to as “overmethylation,” may paradoxically contribute to elevated homocysteine levels.

Another relevant mechanism involves impaired transsulfuration. Even in the presence of adequate vitamin B6 levels, oxidative stress, inflammation, or genetic factors may reduce CBS activity, limiting the conversion of homocysteine into cysteine and glutathione [5]. This results in accumulation of homocysteine despite adequate upstream support.

Additionally, systemic factors such as insulin resistance, hypothyroidism, renal dysfunction, and chronic inflammation may contribute to altered homocysteine metabolism and should be considered in resistant cases [13].

7. A PRACTICAL CLINICAL APPROACH TO RESISTANT CASES

In patients with persistent hyperhomocysteinemia despite adequate supplementation, a shift in therapeutic strategy is warranted. Rather than escalating doses, a reduction in excessive methyl donors may restore metabolic balance and improve pathway efficiency.

This approach involves reassessing the total methylation burden and avoiding unnecessary or redundant supplementation (see Figure 2 for a practical algorithm).

Simultaneously, supporting the transsulfuration pathway becomes essential. The use of N-acetylcysteine and glycine may enhance glutathione synthesis and facilitate homocysteine clearance by promoting downstream metabolic flow. Magnesium may also contribute to enzymatic function and overall metabolic stability.

Adjustments in the form and dose of vitamins should also be considered. For instance, switching from methylcobalamin to hydroxocobalamin may reduce excessive methylation drive while maintaining adequate cobalamin availability.

Importantly, clinicians should evaluate systemic contributors such as thyroid function, renal status, and inflammatory markers, as addressing these factors may be crucial for metabolic normalization.

8. DISCUSSION: FROM DEFICIENCY TO METABOLIC REGULATION

The management of hyperhomocysteinemia requires a paradigm shift from a simplistic deficiency-based model to a more integrated understanding of metabolic regulation. Persistent elevation of homocysteine in the presence of adequate cofactors suggests that the issue lies not in supply but in utilization and pathway coordination.

This perspective emphasizes the importance of metabolic balance, enzymatic efficiency, and the interaction between methylation and redox systems. In this context, the concept of “less is more” becomes clinically relevant, as reducing supplementation may improve metabolic function by alleviating pathway congestion. These mechanisms are summarized in Figure 1 and translated into clinical decision-making in Figure 2.

9. CONCLUSION

Hyperhomocysteinemia is a complex metabolic condition that cannot always be effectively managed through conventional supplementation strategies. In resistant cases, it reflects a broader disturbance in metabolic regulation involving methylation imbalance, impaired transsulfuration, and systemic factors.

A physiology-based, individualized approach that prioritizes metabolic balance over aggressive supplementation may provide more effective and sustainable outcomes. Further research is needed to better understand these mechanisms and to refine therapeutic strategies for refractory hyperhomocysteinemia.

REFERENCES

1. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke. *JAMA*. 2002;288(16):2015–22.
2. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. *N Engl J Med*. 1998;338(15):1042–50.
3. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease. *BMJ*. 2002;325:1202.
4. Stover PJ. One-carbon metabolism–genome interactions in folate-associated pathologies. *J Nutr*. 2009;139(12):2402–5.
5. Stipanuk MH. Sulfur amino acid metabolism: pathways for production and removal of homocysteine and cysteine. *Annu Rev Nutr*. 2004;24:539–77.
6. Tyagi SC. Homocysteine redox receptor and regulation of extracellular matrix components in vascular cells. *Am J Physiol*. 1998;274:C396–405.
7. Humphrey LL, Fu R, Rogers K, et al. Homocysteine level and coronary heart disease incidence. *Mayo Clin Proc*. 2008;83(11):1203–12.
8. Smith AD, Refsum H. Homocysteine, B vitamins, and cognitive impairment. *Annu Rev Nutr*. 2016;36:211–39.
9. Martí-Carvajal AJ, Solà I, Lathyris D, et al. Homocysteine-lowering interventions for preventing cardiovascular events. *Cochrane Database Syst Rev*. 2017;8:CD006612.
10. Clarke R, Halsey J, Lewington S, et al. Effects of lowering homocysteine levels with B vitamins. *Arch Intern Med*. 2010;170(18):1622–31.
11. McNulty H, Dowey le RC, Strain JJ, et al. Riboflavin lowers homocysteine in MTHFR genotype. *Am J Clin Nutr*. 2006;84(4):863–8.
12. Bottiglieri T. S-Adenosyl-L-methionine (SAMe): from the bench to the bedside. *Am J Clin Nutr*. 2002;76(5):1151S–1157S.
13. Selhub J. Homocysteine metabolism. *Annu Rev Nutr*. 1999;19:217–46.



Figure 1 legend. Schematic representation of homocysteine metabolism, including remethylation and transsulfuration pathways, with key enzymes and cofactors.



Figure 2 legend. Practical clinical approach to resistant hyperhomocysteinemia, highlighting diagnostic and therapeutic steps.